Narcotic antagonist activity of substituted 1,2,4,5-tetrahydro-3H,3-benzazepines.
D000700:Analgesics / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000138:chemical synthesis / Q000302:isolation & purification / Q000494:pharmacology*; D003460:Crystallization; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051379:Mice; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009184:Mydriatics / Q000037:antagonists & inhibitors; D009269:Nalorphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010111:Oxymorphone / Q000037:antagonists & inhibitors; D010423:Pentazocine / Q000494:pharmacology; D011817:Rabbits; D012018:Reflex / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D013329:Structure-Activity Relationship; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced; D013623:Tail; D013997:Time Factors
D000700:Analgesics; D001552:Benzazepines; D009184:Mydriatics; D009292:Narcotic Antagonists; D009270:Naloxone; D009020:Morphine; D010111:Oxymorphone; D010423:Pentazocine; D009269:Nalorphine